ARK-FutureFirst
๐™‚๐™–๐™ข๐™š ๐˜พ๐™๐™–๐™ฃ๐™œ๐™š๐™ง! ๐™๐˜ฟ๐˜ผ ๐™‹๐™๐™–๐™จ๐™ž๐™ฃ๐™œ ๐™Š๐™ช๐™ฉ ๐˜ผ๐™ฃ๐™ž๐™ข๐™–๐™ก ๐™๐™š๐™จ๐™ฉ๐™ž๐™ฃ๐™œ ๐™›๐™ค๐™ง ๐˜ผ๐™„ & ๐™ƒ๐™ช๐™ข๐™–๐™ฃ-๐™๐™š๐™ก๐™š๐™ซ๐™–๐™ฃ๐™ฉ ๐˜ฟ๐™ง๐™ช๐™œ ๐˜ฟ๐™š๐™ซ๐™š๐™ก๐™ค๐™ฅ๐™ข๐™š๐™ฃ๐™ฉ ๐Ÿš€ ๐™ƒ๐™ช๐™œ๐™š ๐™ฃ๐™š๐™ฌ๐™จ ๐™›๐™ง๐™ค๐™ข ๐™ฉ๐™๐™š ๐™๐˜ฟ๐˜ผ! As of April 10, 2025, the U.S. Food and Drug Administration announced a groundbreaking plan to phase out mandatory animal testing for monoclonal antibodies and other drugs. This marks a monumental shift towards "more effective, human-relevant" methods like AI models and lab-grown human cell systems. ๐™’๐™๐™ฎ ๐™ฉ๐™๐™ž๐™จ ๐™ข๐™–๐™ฉ๐™ฉ๐™š๐™ง๐™จ: Faster & Cheaper Drug Development: This innovation-driven policy should significantly cut the time and cost of bringing new, life-saving drugs to market. Massive ROI for AI Biotech: Our analysis suggests AI-developed therapeutics could boost returns on investment by 5x (to over 20% from ~4%), potentially reducing overall development costs by four-fold! Unlocking Rare Disease Treatments: With reduced costs and accelerated timelines, AI could enable biotech companies to profitably address 75% of the rare disease patient population, dramatically expanding access to therapies where only ~5% currently exist. Enhanced Patient Outcomes: More effective, accessible treatments mean improved quality of life and reduced healthcare costs. This isn't just a regulatory change; it's the dawn of a new era for molecular medicine, powered by rapid advancements in AI, multiomics, and microphysiological systems. Companies already leveraging AI in drug discovery like AbSci, AbCellera, and Recursion Pharmaceuticals, as well as multiomics tool providers, stand to benefit immensely. ๐™๐™๐™š ๐™๐˜ฟ๐˜ผ'๐™จ ๐™˜๐™ค๐™ข๐™ข๐™ž๐™ฉ๐™ข๐™š๐™ฃ๐™ฉ ๐™ฉ๐™ค ๐™ž๐™ฃ๐™ฃ๐™ค๐™ซ๐™–๐™ฉ๐™ž๐™ค๐™ฃ ๐™ข๐™š๐™–๐™ฃ๐™จ ๐™›๐™–๐™จ๐™ฉ๐™š๐™ง, ๐™ข๐™ค๐™ง๐™š ๐™–๐™˜๐™˜๐™ช๐™ง๐™–๐™ฉ๐™š, ๐™–๐™ฃ๐™™ ๐™ข๐™ค๐™ง๐™š ๐™˜๐™ค๐™จ๐™ฉ-๐™š๐™›๐™›๐™š๐™˜๐™ฉ๐™ž๐™ซ๐™š ๐™™๐™ง๐™ช๐™œ ๐™™๐™š๐™ซ๐™š๐™ก๐™ค๐™ฅ๐™ข๐™š๐™ฃ๐™ฉ ๐™ฉ๐™๐™–๐™ฉ ๐™—๐™š๐™ฃ๐™š๐™›๐™ž๐™ฉ๐™จ ๐™š๐™ซ๐™š๐™ง๐™ฎ๐™ค๐™ฃ๐™š โ€“ ๐™›๐™ง๐™ค๐™ข ๐™ž๐™ฃ๐™ฃ๐™ค๐™ซ๐™–๐™ฉ๐™ค๐™ง๐™จ ๐™ฉ๐™ค ๐™ฅ๐™–๐™ฉ๐™ž๐™š๐™ฃ๐™ฉ๐™จ ๐™–๐™ฃ๐™™ ๐™ฉ๐™๐™š ๐™š๐™ฃ๐™ฉ๐™ž๐™ง๐™š ๐™๐™š๐™–๐™ก๐™ฉ๐™๐™˜๐™–๐™ง๐™š ๐™จ๐™ฎ๐™จ๐™ฉ๐™š๐™ข. ๐™๐™š๐™–๐™™ ๐™ˆ๐™ค๐™ง๐™š: europe.ark-funds.com/2025/05/from-animals-to-ai-the-fdas-new-policy-should-transform-the-drug-development-process/
Like CommentShare
4 replies
null
.